Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-1039 in advanced endometrial cancer
NCT01244438Phase 2Withdrawn
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Jan 2011
- Primary completion
- Jun 2012
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of FP-1039 in endometrial cancer (EC), sponsored by Five Prime Therapeutics, Inc.. Planned start Jan 2011; status: withdrawn.
02
Drugs
FP-1039
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT01244438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01244438.